Champions Oncology, Inc.
Champions Oncology, Inc. (Nasdaq: CSBR) provides technology-enabled research solutions for oncology drug discovery and development. Its platforms combine experimental research, computational tools and a proprietary bank of approximately 1,500 patient-derived xenograft (PDX) tumor models with molecular, clinical and… From the company’s description.
Over the twelve months to Jul 31, 2026, Champions Oncology, Inc. reported revenue of $60.66M, up 6.7% from a year earlier, and a net loss of $1.14M. Its operating margin was −1.7%, and operations used $5.56M in cash. In fiscal 2025, it reported revenue of $59.42M, up 4.4% from fiscal 2024, and a net loss of $1.18M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Champions Oncology, Inc. does
In the company’s own words
Champions Oncology, Inc. (Nasdaq: CSBR) provides technology-enabled research solutions for oncology drug discovery and development. Its platforms combine experimental research, computational tools and a proprietary bank of approximately 1,500 patient-derived xenograft (PDX) tumor models with molecular, clinical and pharmacological data. The company’s business includes research services for pharmaceutical and biotechnology companies, licenses to PDX model data, subscriptions to its Lumin Bioinformatics software, and early-stage discovery and development of oncology therapeutics. Research services use in vivo, ex vivo and computational studies to assess drug activity, identify potential patient groups and develop biomarker hypotheses; this is the company’s primary revenue source. Lumin supports computational cancer research using analytics and artificial intelligence, while therapeutic research focuses on drug conjugates, immuno-oncology and cell therapy. The company reports revenue of approximately $59.4 million for fiscal 2026. It has approximately 3,500 proprietary molecular datasets and about 20,000 publicly available datasets in its oncology Datacenter. Its website is www.championsoncology.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- BALTIMORE, MD
- Fiscal year end
- April
- CIK
- 771856
- SIC
- 2836
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Champions Oncology, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Champions Oncology, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Champions Oncology, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Champions Oncology, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Champions Oncology, Inc.'s last four quarterly filings that the numbers alone won't show?”